Protein and antibody engineering at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

39 organizations at PEGS Europe 2026 present work in protein and antibody engineering: 16 suppliers and service providers, 12 drug developers and 11 academic, government and non-profit bodies. Between them they bring 63 presentations to the program. Most represented: Regeneron (4 on the program), Specifica (3 on the program), Chugai Pharmaceutical (3 on the program). As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–11 of 39 organizations

Organization	PEGS Europe 2026 Attendance
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company with marketed antibody medicines, discovered with its VelocImmune mice, and a pipeline including CD3 bispecifics.	Talk Tue Nov 17 11:15am–11:45am Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm A Novel Approach to Enhance Tissue Specific Gene Delivery Biologics for Autoimmune Diseases Talk Wed Nov 18 6:00pm–6:30pm Advancing CD3 Bispecifics for Solid Tumour Indications Engineering Antibodies & Beyond
Specifica Santa Fe, NM
specifica.bio Discovery platforms IQVIA antibody discovery business offering Generation 3 and VHH display libraries, discovery and optimisation services, and platform transfer.	Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with AstraZeneca, Merck KGaA, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Talk Wed Nov 18 12:15pm–12:45pm Evolution of Specifica’s Gen3 Technology: Functional Bispecifics Directly from Constant Light Chain Libraries Engineering Antibodies & Beyond Panel Thu Nov 19 3:36pm–4:14pm Appropriate Use of Agentic AI in the Lab Machine Learning for Protein Engineering Part 2 · with Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Chair Thu Nov 19 4:14pm–4:15pm Chairperson's Remarks Machine Learning for Protein Engineering Part 2
Chugai Pharmaceutical Tokyo, Japan
chugai-pharm.co.jp Large pharma Japanese pharmaceutical company in the Roche group, known for antibody engineering technologies such as recycling and bispecific antibodies.	Talk Wed Nov 18 8:30am–9:00am Empowering Next-Generation Antibodies: Synergy of Conditional Activation and Fc Engineering Engineering Antibodies & Beyond Talk Wed Nov 18 8:30am–9:00am Strategy for Evaluating Undesired Mis-Paired Variants across Bispecific Antibody Modalities Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 2:35pm–3:05pm Molecular Dynamics Analysis toward Understanding Formulation-Dependent DSC Behaviour of Antibodies Protein Stability & Formulation
University of Southampton Southampton, UK
	Talk Wed Nov 18 9:30am–10:00am Antibody Properties That Control Immune Receptor Signalling: Lessons from Affinity, Rigidity, and Geometry Engineering Antibodies & Beyond Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Engineering Antibodies & Beyond · with IQS – Universitat Ramon Llull Talk Thu Nov 19 4:15pm–4:45pm Platforms for the Intracellular Generation and High-Throughput Screening of Cyclic Peptide Libraries Novel Peptide Drug Discovery Talk Thu Nov 19 4:45pm–5:15pm A "Function-First" Approach to Identify Regulatory T Cell-Targeting Antibodies for Immunotherapy Antibodies Against Challenging Targets
Denali Therapeutics South San Francisco, CA
denalitherapeutics.com Biotech Develops medicines for neurodegenerative and lysosomal diseases, using its Transport Vehicle platform to carry biologics across the blood–brain barrier.	Talk Thu Nov 19 11:45am–12:15pm Dual Targeting of Transferrin Receptor and CD98hc Enhances Brain Exposure of Large Molecules Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 2:05pm–2:35pm Transferrin Receptor–Mediated Transport Vehicles Enable Delivery of Therapeutic Enzymes to the CNS and Peripheral Tissues Antibodies Against Challenging Targets Panel Thu Nov 19 3:35pm–4:15pm Brain Delivery of Complex Biotherapeutics: Scientific Challenges and Future Opportunities Antibodies Against Challenging Targets
FairJourney Biologics Porto, Portugal	◆Corporate Sponsor
fjbio.com CRO & CDMOCorporate Sponsor Antibody discovery and engineering CRO running phage display, immunisation and optimisation campaigns for drug developers.	Booth Exhibiting at Booth 325 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Wed Nov 18 10:00am–10:30am Talk Title to be Announced Engineering Antibodies & Beyond Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Biologics for Autoimmune Diseases
Integral Molecular Philadelphia, PA	◆Premier Sponsor
integralmolecular.com CRO & CDMOPremier Sponsor Discovers antibodies against membrane proteins and tests antibody specificity with its Membrane Proteome Array.	Booth Exhibiting at Booth 233 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Tue Nov 17 12:15pm–12:45pm 1 in 3 MAbs Binds Off-Target: How to Predict and Avoid Adverse Events Caused by Polyspecificity Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Wed Nov 18 12:15pm–12:45pm 100+ Undruggable Targets Unlocked through Parallel MAb Engineering Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Nuclera Cambridge, UK	◆Corporate Sponsor
nuclera.com Instruments & analyticsCorporate Sponsor Makes the eProtein Discovery benchtop system, which combines cell-free expression and digital microfluidics to screen protein constructs within days.	Booth Exhibiting at Booth 313 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Wed Nov 18 6:30pm–7:00pm Rapid Cell-Free Screening of AI Designed Antibody Panels Engineering Antibodies & Beyond Talk Thu Nov 19 12:15pm–12:45pm From DNA to Active GPCR in 48 Hours Highly Parallel Protein Discovery Workflows
CNRS Paris, France
cnrs.fr Academic France's national centre for scientific research, running laboratories across all fields, many jointly with universities.	Talk Tue Nov 17 2:05pm–2:35pm From Data Science to Fine-Tuning Codon Optimization for High-Yield Protein Production in E. coli Leveraging Data Science for Enhanced Protein Expression Talk Thu Nov 19 11:45am–12:15pm Nanobody Therapy Rescues Behavioural Deficits of NMDA Receptor Hypofunction Antibodies Against Challenging Targets
Cullinan Therapeutics Cambridge, MA
cullinantherapeutics.com Biotech Biotech developing T cell engagers and other targeted therapies for autoimmune diseases and cancer.	Talk Wed Nov 18 11:45am–12:15pm A New Frontier for the Treatment of Autoimmune Diseases: T Cell Engager Therapies Targeting CD19 or BCMA Biologics for Autoimmune Diseases Talk Wed Nov 18 4:00pm–4:10pm The Future of T Cell Engagers Plenary Bispecifics, multispecifics and T cell engagersOncology and immunotherapy Panel Wed Nov 18 4:10pm–4:50pm Emerging Modalities and the Future of Antibody Engineering Plenary · with Stanford University, University of Stuttgart, Johnson & Johnson Innovative Medicine Protein and antibody engineering
University of Minnesota Twin Cities Minneapolis, MN
	Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Engineering Antibodies & Beyond Talk Wed Nov 18 7:00pm–7:30pm Engineering Bispecific Binding in a Single Domain Antibody via a Novel Paratope Engineering Antibodies & Beyond Panel Thu Nov 19 3:35pm–4:15pm Novel AI Architecture for Protein Stability Design Protein Stability & Formulation